South African COVID variant might evade protection from vaccine, study finds

The South Africa variant of the coronavirus might evade the Pfizer vaccine, according to a new study from Tel Aviv University and Israel’s largest healthcare provider.

The study, which was published Saturday and still requires peer review, looked at 400 individuals who tested positive for the coronavirus despite receiving at least one dose of the Pfizer/BioNTech vaccine and compared the prevalence of the South African variant, B.1.351, with the same number of people who have not yet received a vaccination.